AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie income Statement — Net revenues ($M) ($M)
Form 10-Q / 10-K Consolidated Statements of Earnings (DB)
Latest, Q2 2026
16,990
Period ended Jun 30, 2026
Change on a year earlier
+10.2%
15,423 in Q2 2025
History
58 quarters
Since Q1 2012
Sources
54
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Income Statement — Net revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 16,990 | +10.2% | Form 10-Q (filed 2026-08-03) ↗ |
| Q1 2026 | Mar 31, 2026 | 15,002 | +12.4% | Form 10-Q (filed 2026-05-08) ↗ |
| Q4 2025 | Dec 31, 2025 | 16,618 | +10.0% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2025 | Sep 30, 2025 | 15,776 | +9.1% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2025 | Jun 30, 2025 | 15,423 | +6.6% | Form 10-Q (filed 2025-08-04) ↗ |
| Q1 2025 | Mar 31, 2025 | 13,343 | +8.4% | Form 10-Q (filed 2025-05-09) ↗ |
| Q4 2024 | Dec 31, 2024 | 15,102 | +5.6% | Form 10-K (filed 2025-02-14) ↗ |
| Q3 2024 | Sep 30, 2024 | 14,460 | +3.8% | Form 10-Q (filed 2024-11-04) ↗ |
| Q2 2024 | Jun 30, 2024 | 14,462 | +4.3% | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2024 | Mar 31, 2024 | 12,310 | +0.7% | Form 10-Q (filed 2024-05-03) ↗ |
| Q4 2023 | Dec 31, 2023 | 14,301 | -5.4% | Form 10-K (filed 2024-02-20) ↗ |
| Q3 2023 | Sep 30, 2023 | 13,927 | -6.0% | Form 10-Q (filed 2023-11-06) ↗ |
| Q2 2023 | Jun 30, 2023 | 13,865 | -4.9% | Form 10-Q (filed 2023-08-07) ↗ |
| Q1 2023 | Mar 31, 2023 | 12,225 | -9.7% | Form 10-Q (filed 2023-05-05) ↗ |
| Q4 2022 | Dec 31, 2022 | 15,121 | +1.6% | Form 10-K (filed 2023-02-17) ↗ |
| Q3 2022 | Sep 30, 2022 | 14,812 | +3.3% | Form 10-Q (filed 2022-11-04) ↗ |
| Q2 2022 | Jun 30, 2022 | 14,583 | +4.5% | Form 10-Q (filed 2022-08-04) ↗ |
| Q1 2022 | Mar 31, 2022 | 13,538 | +4.1% | Form 10-Q (filed 2022-05-06) ↗ |
| Q4 2021 | Dec 31, 2021 | 14,886 | +7.4% | Form 10-K (filed 2022-02-18) ↗ |
| Q3 2021 | Sep 30, 2021 | 14,342 | +11.2% | Form 10-Q (filed 2021-11-02) ↗ |
| Q2 2021 | Jun 30, 2021 | 13,959 | +33.9% | Form 10-Q (filed 2021-08-02) ↗ |
| Q1 2021 | Mar 31, 2021 | 13,010 | +50.9% | Form 10-Q (filed 2021-05-07) ↗ |
| Q4 2020 | Dec 31, 2020 | 13,858 | +59.2% | Form 10-K (filed 2021-02-19) ↗ |
| Q3 2020 | Sep 30, 2020 | 12,902 | +52.2% | Form 10-Q (filed 2020-11-04) ↗ |
| Q2 2020 | Jun 30, 2020 | 10,425 | +26.3% | Form 10-Q (filed 2020-08-04) ↗ |
| Q1 2020 | Mar 31, 2020 | 8,619 | +10.1% | Form 10-Q (filed 2020-05-08) ↗ |
| Q4 2019 | Dec 31, 2019 | 8,704 | +4.8% | Form 10-K (filed 2020-02-21) ↗ |
| Q3 2019 | Sep 30, 2019 | 8,479 | +3.0% | Form 10-Q (filed 2019-11-06) ↗ |
| Q2 2019 | Jun 30, 2019 | 8,255 | -0.3% | Form 10-Q (filed 2019-08-05) ↗ |
| Q1 2019 | Mar 31, 2019 | 7,828 | -1.3% | Form 10-Q (filed 2019-05-03) ↗ |
| Q4 2018 | Dec 31, 2018 | 8,305 | +7.3% | Form 10-K (filed 2019-02-27) ↗ |
| Q3 2018 | Sep 30, 2018 | 8,236 | +17.7% | Form 10-Q (filed 2018-11-07) ↗ |
| Q2 2018 | Jun 30, 2018 | 8,278 | +19.2% | Form 10-Q (filed 2018-08-07) ↗ |
| Q1 2018 | Mar 31, 2018 | 7,934 | +21.4% | Form 10-Q (filed 2018-05-04) ↗ |
| Q4 2017 | Dec 31, 2017 | 7,739 | +13.9% | Form 10-K (filed 2018-02-16) ↗ |
| Q3 2017 | Sep 30, 2017 | 6,995 | +8.8% | Form 10-Q (filed 2017-11-07) ↗ |
| Q2 2017 | Jun 30, 2017 | 6,944 | +7.6% | Form 10-Q (filed 2017-08-07) ↗ |
| Q1 2017 | Mar 31, 2017 | 6,538 | +9.7% | Form 10-Q (filed 2017-05-05) ↗ |
| Q4 2016 | Dec 31, 2016 | 6,796 | +6.2% | Form 10-K (filed 2017-02-17) ↗ |
| Q3 2016 | Sep 30, 2016 | 6,432 | +8.2% | Form 10-Q (filed 2016-11-07) ↗ |
| Q2 2016 | Jun 30, 2016 | 6,452 | +17.8% | Form 10-Q (filed 2016-08-05) ↗ |
| Q1 2016 | Mar 31, 2016 | 5,958 | +18.2% | Form 10-Q (filed 2016-05-06) ↗ |
| Q4 2015 | Dec 31, 2015 | 6,400 | +17.4% | Form 10-K (filed 2016-02-19) ↗ |
| Q3 2015 | Sep 30, 2015 | 5,944 | +18.4% | Form 10-Q (filed 2015-11-06) ↗ |
| Q2 2015 | Jun 30, 2015 | 5,475 | +11.1% | Form 10-Q (filed 2015-08-07) ↗ |
| Q1 2015 | Mar 31, 2015 | 5,040 | +10.5% | Form 10-Q (filed 2015-05-08) ↗ |
| Q4 2014 | Dec 31, 2014 | 5,452 | +6.7% | Form 10-K (filed 2015-02-20) ↗ |
| Q3 2014 | Sep 30, 2014 | 5,019 | +7.8% | Form 10-Q (filed 2014-11-07) ↗ |
| Q2 2014 | Jun 30, 2014 | 4,926 | +5.0% | Form 10-Q (filed 2014-08-07) ↗ |
| Q1 2014 | Mar 31, 2014 | 4,563 | +5.4% | Form 10-Q (filed 2014-05-09) ↗ |
| Q4 2013 | Dec 31, 2013 | 5,111 | -1.8% | Form 10-K (filed 2014-02-21) ↗ |
| Q3 2013 | Sep 30, 2013 | 4,658 | +3.3% | Form 10-Q (filed 2013-11-12) ↗ |
| Q2 2013 | Jun 30, 2013 | 4,692 | +4.4% | Form 10-Q (filed 2013-08-09) ↗ |
| Q1 2013 | Mar 31, 2013 | 4,329 | +3.7% | Form 10-Q (filed 2013-05-08) ↗ |
| Q4 2012 | Dec 31, 2012 | 5,206 | – | Form 10-K (filed 2014-02-21) ↗ |
| Q3 2012 | Sep 30, 2012 | 4,508 | – | Form 10-Q (filed 2013-11-12) ↗ |
| Q2 2012 | Jun 30, 2012 | 4,493 | – | Form 10-Q (filed 2013-08-09) ↗ |
| Q1 2012 | Mar 31, 2012 | 4,173 | – | Form 10-Q (filed 2013-05-08) ↗ |
Breakdown
What makes up income statement — net revenues ($m)
- Cost of products sold ($M)4,291 · Q2 2026
- Total operating costs and expenses ($M)10,558 · Q2 2026
- Selling, general and administrative expense ($M)3,632 · Q2 2026
- Research and development expense ($M)2,344 · Q2 2026
- Operating earnings ($M)6,432 · Q2 2026
- Interest expense ($M)746 · Q2 2026
- Interest income ($M)67 · Q2 2026
- Earnings before income tax ($M)4,278 · Q2 2026
- Income tax expense ($M)662 · Q2 2026
- Net earnings attributable to AbbVie Inc. ($M)3,601 · Q2 2026
- Earnings per share — Basic ($/sh)2.04 · Q2 2026
- Earnings per share — Diluted ($/sh)2.03 · Q2 2026
- Weighted-average basic shares outstanding (M)1,769.00 · Q2 2026
- Weighted-average diluted shares outstanding (M)1,771.00 · Q2 2026
Cite this data
StockData. (2026). AbbVie Income Statement — Net revenues ($M) ($M), quarterly Q1 2012–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/fs_income_stmt
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.